In recent years, the increase in R&D expenditures for pharmaceuticals and medical devices has stimulated innovation, thereby increasing demand for R&D outsourcing services. As innovative healthcare enterprises continue to increase their R&D spending, R&D outsourcing services will benefit more from favorable government policies. Preclinical research of drugs mainly consists of pharmacodynamic studies (DMPK), toxicological safety evaluations, and chemical composition production and control (CMC). In addition to drugs, preclinical research of medical devices has also become an important part of the value chain of medical device R&D. Driven by factors such as the increasing demand for preclinical animal experiments, the continuous development of the innovative drug industry, the continuous upgrading of technologies used in preclinical evaluation, and other factors, the demand for preclinical R&D outsourcing services for pharmaceuticals and medical devices in China will continue to grow, with a huge market space. Frost & Sullivan (Frost & Sullivan) hereby releases an independent research report titled 'Market Research Report on Preclinical R&D Outsourcing Services for Pharmaceuticals and Medical Devices'.
The attachment is an excerpted version of the report. If you have further research needs on the preclinical R&D outsourcing services market for pharmaceuticals and medical devices in China, please contact us at any time:
Mr. Mao from Frost & Sullivan
Tel: (+86) 159 2139 6033
E-mail: fred.mao@frostchina.com
